BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 26731611)

  • 1. 4-Acyl Pyrrole Derivatives Yield Novel Vectors for Designing Inhibitors of the Acetyl-Lysine Recognition Site of BRD4(1).
    Hügle M; Lucas X; Weitzel G; Ostrovskyi D; Breit B; Gerhardt S; Einsle O; Günther S; Wohlwend D
    J Med Chem; 2016 Feb; 59(4):1518-30. PubMed ID: 26731611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular docking and dynamics simulation study of flavonoids as BET bromodomain inhibitors.
    Raj U; Kumar H; Varadwaj PK
    J Biomol Struct Dyn; 2017 Aug; 35(11):2351-2362. PubMed ID: 27494802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation.
    Xue X; Zhang Y; Liu Z; Song M; Xing Y; Xiang Q; Wang Z; Tu Z; Zhou Y; Ding K; Xu Y
    J Med Chem; 2016 Feb; 59(4):1565-79. PubMed ID: 26731490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In silico study directed towards identification of novel high-affinity inhibitors targeting an oncogenic protein: BRD4-BD1.
    Tumdam R; Kumar A; Subbarao N; Balaji BS
    SAR QSAR Environ Res; 2018 Dec; 29(12):975-996. PubMed ID: 30411639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In silico design and bioevaluation of selective benzotriazepine BRD4 inhibitors with potent antiosteoclastogenic activity.
    Deepak V; Wang B; Koot D; Kasonga A; Stander XX; Coetzee M; Stander A
    Chem Biol Drug Des; 2017 Jul; 90(1):97-111. PubMed ID: 28032455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and biological evaluation of novel 4-phenylisoquinolinone BET bromodomain inhibitors.
    Bennett MJ; Wu Y; Boloor A; Matuszkiewicz J; O'Connell SM; Shi L; Stansfield RK; Del Rosario JR; Veal JM; Hosfield DJ; Xu J; Kaldor SW; Stafford JA; Betancort JM
    Bioorg Med Chem Lett; 2018 Jun; 28(10):1811-1816. PubMed ID: 29657099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of 4,5-dihydro-benzodiazepinone derivatives as a new chemical series of BRD4 inhibitors.
    Li J; Wang P; Zhou B; Shi J; Liu J; Li X; Fan L; Zheng Y; Ouyang L
    Eur J Med Chem; 2016 Oct; 121():294-299. PubMed ID: 27266999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of a new chemical series of BRD4(1) inhibitors using protein-ligand docking and structure-guided design.
    Duffy BC; Liu S; Martin GS; Wang R; Hsia MM; Zhao H; Guo C; Ellis M; Quinn JF; Kharenko OA; Norek K; Gesner EM; Young PR; McLure KG; Wagner GS; Lakshminarasimhan D; White A; Suto RK; Hansen HC; Kitchen DB
    Bioorg Med Chem Lett; 2015 Jul; 25(14):2818-23. PubMed ID: 26022843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors.
    Ember SW; Zhu JY; Olesen SH; Martin MP; Becker A; Berndt N; Georg GI; Schönbrunn E
    ACS Chem Biol; 2014 May; 9(5):1160-71. PubMed ID: 24568369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4-Acyl Pyrroles as Dual BET-BRD7/9 Bromodomain Inhibitors Address BETi Insensitive Human Cancer Cell Lines.
    Hügle M; Regenass P; Warstat R; Hau M; Schmidtkunz K; Lucas X; Wohlwend D; Einsle O; Jung M; Breit B; Günther S
    J Med Chem; 2020 Dec; 63(24):15603-15620. PubMed ID: 33275431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
    Ran X; Zhao Y; Liu L; Bai L; Yang CY; Zhou B; Meagher JL; Chinnaswamy K; Stuckey JA; Wang S
    J Med Chem; 2015 Jun; 58(12):4927-39. PubMed ID: 26080064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylpyrrole inhibitors of BET bromodomains.
    Hasvold LA; Sheppard GS; Wang L; Fidanze SD; Liu D; Pratt JK; Mantei RA; Wada CK; Hubbard R; Shen Y; Lin X; Huang X; Warder SE; Wilcox D; Li L; Buchanan FG; Smithee L; Albert DH; Magoc TJ; Park CH; Petros AM; Panchal SC; Sun C; Kovar P; Soni NB; Elmore SW; Kati WM; McDaniel KF
    Bioorg Med Chem Lett; 2017 May; 27(10):2225-2233. PubMed ID: 28268136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands.
    Hewings DS; Fedorov O; Filippakopoulos P; Martin S; Picaud S; Tumber A; Wells C; Olcina MM; Freeman K; Gill A; Ritchie AJ; Sheppard DW; Russell AJ; Hammond EM; Knapp S; Brennan PE; Conway SJ
    J Med Chem; 2013 Apr; 56(8):3217-27. PubMed ID: 23517011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and Bromodomains.
    Wang J; Erazo T; Ferguson FM; Buckley DL; Gomez N; Muñoz-Guardiola P; Diéguez-Martínez N; Deng X; Hao M; Massefski W; Fedorov O; Offei-Addo NK; Park PM; Dai L; DiBona A; Becht K; Kim ND; McKeown MR; Roberts JM; Zhang J; Sim T; Alessi DR; Bradner JE; Lizcano JM; Blacklow SC; Qi J; Xu X; Gray NS
    ACS Chem Biol; 2018 Sep; 13(9):2438-2448. PubMed ID: 30102854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and biological evaluation of benzo[cd]indol-2(1H)-ones derivatives as BRD4 inhibitors.
    Feng Y; Xiao S; Chen Y; Jiang H; Liu N; Luo C; Chen S; Chen H
    Eur J Med Chem; 2018 May; 152():264-273. PubMed ID: 29730189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring Selective Inhibition of the First Bromodomain of the Human Bromodomain and Extra-terminal Domain (BET) Proteins.
    Raux B; Voitovich Y; Derviaux C; Lugari A; Rebuffet E; Milhas S; Priet S; Roux T; Trinquet E; Guillemot JC; Knapp S; Brunel JM; Fedorov AY; Collette Y; Roche P; Betzi S; Combes S; Morelli X
    J Med Chem; 2016 Feb; 59(4):1634-41. PubMed ID: 26735842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, Synthesis, and in vitro Biological Evaluation of 3,5-Dimethylisoxazole Derivatives as BRD4 Inhibitors.
    Li X; Zhang J; Zhao L; Yang Y; Zhang H; Zhou J
    ChemMedChem; 2018 Jul; 13(13):1363-1368. PubMed ID: 29808961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BET bromodomain inhibitors: a patent review.
    Garnier JM; Sharp PP; Burns CJ
    Expert Opin Ther Pat; 2014 Feb; 24(2):185-99. PubMed ID: 24261714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting BET bromodomains for cancer treatment.
    Jung M; Gelato KA; Fernández-Montalván A; Siegel S; Haendler B
    Epigenomics; 2015; 7(3):487-501. PubMed ID: 26077433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based virtual screening of novel, high-affinity BRD4 inhibitors.
    Muvva C; Singam ER; Raman SS; Subramanian V
    Mol Biosyst; 2014 Jul; 10(9):2384-97. PubMed ID: 24976024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.